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Abstract: A i m: Our aim was to determine serum concentrations of tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) and its decoy receptor osteoprotegerin (OPG) in patients with mild 
and moderate to severe acute pancreatitis (AP) in the early phase of the disease.
M a t e r i a l s  a n d  m e t h o d s: We included 40 patients with AP (16 women, 24 men) admitted to 
Ist Department of Surgery, Jagiellonian University Medical College, Krakow. Twenty-eight had mild 
(MAP) and twelve moderate to severe form of AP (SAP). Serum concentrations of OPG and TRAIL were 
measured by ELISA at admission and on days 3, 5 and 7.
R e s u l t s: Both TRAIL and OPG were elevated in AP patients as compared to reference values. Starting 
from day 3 of the study, OPG concentrations were significantly higher in SAP than in MAP. Also, 
day 3 OPG was higher in patients who died from AP. OPG positively correlated with Glasgow score, 
C-reactive protein (CRP) concentrations and length of hospital stay. Day 3 OPG cut-off of 713 pg/mL 
enabled to differentiate between SAP and MAP with sensitivity of 71% and specificity of 80%. Area 
under ROC curve was 0.795, comparable to that achieved for CRP (0.838; p >0.05). In contrast, serum 
concentrations of TRAIL were not associated with AP severity.
C o n c l u s i o n s: Determination of serum OPG concentrations may help in early prediction of severity 
of AP. However, diagnostic utility of the measurements seems too low to use OPG as a single clinically 
reliable predictor. Serum TRAIL is not useful in the differentiation between mild and severe form of AP.
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INTRODUCTION
Acute pancreatitis (AP) is a potentially fatal disease. Although most patients re-
cover without complications (mild acute pancreatitis — MAP), in about 20–25% 
of patients the disease evolve into moderately severe or severe form (SAP), asso-
ciated with transient or persistent organ failure and local complications. Severe 
acute pancreatitis is associated with high mortality, reaching 50% [1, 2]. Factors 
determining the extend of inflammatory response to pancreatic injury and the 
severity of the disease are not fully understood. However, the earliest events in 
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AP involve an injury of acinar cells, resulting in apoptosis or necrosis. Apoptosis 
of acinar cells appears to be associated with mild disease, while in severe form 
of AP necrosis prevails [2, 3]. As shown in animal experiments, early induction of 
apoptosis during the course of AP may have beneficial effect on the outcome [4]. 
On the other hand, the development of systemic complications in SAP may be 
associated with apoptosis affecting distant tissues and organs, such as lung, 
kidney, intestine or liver [5–7].
Apoptosis, a programmed cell-death, may be triggered by internal or external 
factors. The external pathway requires binding of death receptors with their li-
gands. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a mem-
ber of tumor necrosis factor (TNF) superfamily, is able to induce apoptosis via 
TRAIL receptor 1 (TRAIL-R1) and TRAIL-R2 while TRAIL-R3 and TRAIL-R4 do 
not transduce the apoptosis signal and may protect cells from TRAIL-induced 
apoptosis [8]. Soluble protein osteoprotegerin (OPG) has been shown to act as 
a decoy receptor for TRAIL [9].
In patients with SAP, early initiated intensive treatment is required. Howev-
er, in clinical practice, early identification of these patients exerts an unresolved 
problem. Clinical scores such as Glasgow, Ranson or Acute Physiology and Chron-
ic Health Evaluation II (APACHE II) as well as C-reactive protein (CRP) measure-
ments that are routinely used for this purpose, enable reliable diagnosis after 
48 hours from the onset of AP [10]. Among various biomarkers studied in this 
context, the members of TNF superfamily, namely, TNF-a, soluble TNF-R I and 
II and TNF-like weak inducer of apoptosis (TWEAK) have shown potential use-
fulness in diagnosis and prognosis of AP [11–13].
In this study, we hypothesized that the serum concentrations of TRAIL and 
its decoy receptor, OPG, may be associated with the severity of AP. Our aim was 
to determine the concentrations of TRAIL and OPG and the ratio of TRAIL/OPG 
in the early phase of AP and to compare them between patients with mild and 
moderate to severe disease.
MATERIALS AND METHODS
STUDIED GROUP
The study involved 40 patients admitted to Ist Department of Surgery, Jagiello-
nian University Medical College, Krakow with AP with the symptoms lasting no 
longer than 12 hours before admission. Twenty-eight patients had mild (MAP) 
and 12 moderate to severe form of AP (SAP). Basic demographic and laborato-
ry characteristics of patients are presented in Table 1. A diagnosis of AP was 
based on clinical history, ultrasound scan and serum lipase or amylase activity 
(at least three times above the reference limit). The progression of morphologi-
cal changes within the pancreas and in the surrounding tissues was evaluated 
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using ultrasound imaging. In all patients ultrasound was performed every day 
during the study period. All patients with the severe form of AP underwent com-
puted tomography (CT). In a few cases, the CT was performed more than once 
and showed the evolution of necrotic changes in the parenchyma of the pancre-
as and in the retroperitoneal and peritoneal spaces. The severity of AP was de-
termined on the basis of repeated clinical examination, laboratory and imaging 
tests, according to the revised Atlanta criteria (2012) [1]. Patients with former-
ly diagnosed liver or kidney failure and those who refused to give the informed 
consent were excluded.
The study protocol has been approved by Jagiellonian University Medical Col-
lege Bioethics Committee (KBET/86/B/2012). The study was conducted in ac-
cordance with the Declaration of Helsinki.
LABORATORY METHODS
The concentrations of OPG and TRAIL were determined in samples collected during 
first week of hospitalization: at admission (i.e. day 1) and on days 3, 5, and 7 of 
hospital stay. The samples were taken together with the blood used for routine 
biochemical tests in order to avoid additional burden for the patients. Twenty 
minutes after drawing, the blood was centrifuged (4000 rotations/minute; 10 min-
utes), the serum was frozen and kept in –70oC until assayed. The measurements 
T a b l e  1
Characteristics of the study group and laboratory parameters at admission.
MAP (N = 28) SAP (N = 12) p
Female/male, N (%) 14 (50)/14 (50) 2 (17)/10 (83) 0.052
Age, years 51.8 ± 15.3 42.1 ± 11.5 0.1
Etiology: biliary/other, N (%) 17 (61)/11 (39) 2 (17)/10 (83) 0.011
Time of hospital stay, days 6 (5–8) 20 (12–47) <0.001
Glasgow score, points 1 (0–1) 2 (1–3) 0.024
Mortality, N (%) 0 6 (50) –
Amylase, U/L 482 (232–1243) 1411 (910–1660) 0.031
Lipase, U/L 925 (663–2400) 1124 (821–5045) 0.4
Albumin, g/L 36.9 ± 4.2 34.6 ± 7.4 0.6
CRP, mg/L 26.9 (10.9–85.5) 106.7 (71.7–235.5) 0.030
MAP — mild acute pancreatitis; SAP — moderate to severe acute pancreatitis; N — number of patients; LDH lactate 
dehydrogenase; CRP — C-reactive protein
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were carried out after all the samples have been collected. The following meth-
ods were used:
— OPG: ELISA method with the use of Human Osteoprotegerin kit (BIOMEDICA 
Medizinproducte GmbH&CoKG, Germany). The reference interval established 
by the manufacturer was 3.77–8.23 pmol/L (75.4–164.6 pg/mL). 
— TRAIL: ELISA method with the use of Human TRAIL/TNFSF10 Quantikine ELISA 
kit (R&D Systems, Minneapolis, USA). The reference interval established by 
the manufacturer was 28–135 pg/mL and the reference interval determined 
by the authors in healthy individuals was 71.87–153.82 pg/mL. 
The measurements of all ELISA micro-plates was performed using Automatic 
Reader (BIO-TEK® Instruments Inc., USA). 
Routine measurements (CRP, amylase, lipase, albumin) were performed on the 
day of blood collection, with the use of routine laboratory methods.
STATISTICAL ANALYSIS
Number of patients (percentage of the appropriate group) are shown for catego-
ries. Quantitative data are presented as median (lower-upper quartile) or mean 
± SD, according to distribution, as tested by Shapiro-Wilk test. Student t-test 
or Mann-Whitney test was used to assess differences between groups. Friedman 
ANOVA with appropriate post-hoc tests was used to compare the results of re-
peated laboratory measurements. Correlations were assessed with Spearman rank 
correlation coefficient. Receiver operating characteristic (ROC) curves were com-
puted to assess the diagnostic utility of selected laboratory tests; the values of 
area under curve (AUC) are reported with 95% confidence interval (95% CI). Re-
sults were considered significant at p <0.05. Computations were performed with 
Statistica 10.0 package (Statsoft Inc., Tulsa, USA).
RESULTS
OPG AND TRAIL CONCENTRATIONS AND OPG/TRAIL RATIOS  
IN PATIENTS WITH SAP AND MAP
Median concentrations of OPG and TRAIL as well as the ratio of OPG/TRAIL in 
AP patients during the early phase of the disease are presented in Table 2. At 
admission (day 1), median concentrations of OPG were almost 3 times higher in 
MAP patients and 4.5 times higher in SAP patients comparing to the upper ref-
erence values. On day 3, we observed further increase in OPG concentrations in 
SAP group (p = 0.047), followed by a decrease on day 7 (p = 0.049). No signif-
icant variability of OPG concentrations was observed in MAP group during the 
study period. Starting from day 3, OPG was higher in SAP than in MAP patients 
(p = 0.031; p = 0.048; p = 0.029 on day 3, 5 and 7, respectively). 
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T a b l e  2 
The concentrations of OPG and TRAIL and OPG/TRAIL ratios in patients with mild and moderate to 
severe acute pancreatitis during first week of the disease.
Day MAP SAP p
OPG, pg/mL
1 447 (345–642) 716 (587–1149) 0.055
3 512 (365–654) 924 (539–1387) 0.031
5 491 (395–724) 953 (483–1924) 0.048
7 422 (369–550) 754 (573–1132) 0.029
TRAIL, pg/mL
1 647 (322–1003) 834 (530–2569) 0.1
3 637 (339–1027) 784 (330–920) 0.8
5 725 (466–1301) 952 (430–1889) 0.6
7 1149 (698–1742) 1108 (920–1889) 0.6
OPG/TRAIL
1 0.45 (0.32–0.94) 0.64 (0.33–1.28) 0.7
3 0.42 (0.35–0.83) 0.78 (0.29–3.14) 0.3
5 0.46 (0.27–0.84) 0.85 (0.26–2.50) 0.3
7 0.22 (0.20–0.56) 0.63 (0.30–1.23) 0.048
MAP — mild acute pancreatitis; SAP — moderate to severe acute pancreatitis; OPG — osteoprotegerin; TRAIL — 
tumor necrosis factor-related apoptosis-inducing ligand
Similarly, compared with upper reference values, TRAIL concentrations at ad-
mission were about 4 and 5.5 times higher in patients with MAP and SAP, re-
spectively. However, TRAIL concentrations did not differ significantly between pa-
tients with MAP and SAP during the early phase of disease. In MAP group, TRAIL 
concentrations on day 7 were significantly higher than the initial concentrations 
(p = 0.032). Similar trend, although non-significant, was observed in SAP group.
Median OPG/TRAIL ratios were consequently higher in SAP patients as com-
pared to MAP, but the groups differed significantly on day 7 only (p = 0.048). 
CORRELATIONS OF OPG, TRAIL AND OPG/TRAIL RATIO  
WITH PARAMETERS RELATED TO SEVERITY OF AP
In the early phase of AP, OPG concentrations positively correlated with Glasgow 
score in the whole group of patients (R = 0.50; p = 0.001 for OPG assessed 
at admission; R = 0.57; p <0.001 on day 3; R = 0.56; p <0.001 on day 5 and 
R = 0.59; p <0.001 on day 7). Similar although less strong correlations were ob-
served for OPG/TRAIL ratio (R = 0.41; p = 0.009; R = 0.48; p = 0.002; R = 0.39; 
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p = 0.013; R = 0.50; p = 0.001, respectively). During the study period, OPG was 
positively correlated with CRP concentrations (R = 0.38; p = 0.016 at admission; 
R = 0.43; p = 0.006 on day 3; R = 0.35; p = 0.027 on day 5; R = 0.67; p <0.001 
on day 7).
Longer hospital stay was associated with higher OPG concentrations on day 3 
(R = 0.46; p = 0.003). Also, OPG concentrations on day 3 were significantly 
higher in patients who died in the course of AP as compared to survivors [1204 
(1021–1387) versus 553 (425–746) pg/mL; p = 0.036]. 
TRAIL serum concentrations were not associated with the measures of AP 
severity. 
DIAGNOSTIC UTILITY OF OPG IN PREDICTION OF AP SEVERITY
Figure 1 shows ROC curves for OPG measurements used to predict AP severity 
(i.e. to diagnose SAP versus MAP). OPG measurements at admission and on days 
Fig. 1. ROC curves showing diagnostic utility of OPG concentrations measured at the early phase of acute 
pancreatitis for the differentiation of mild versus moderate to severe disease. OPG concentrations 
were determined at admission (A), on day 3 (B), 5 (C) and 7 (D). Proposed cut-off values and the 
values of area under curve (AUC) with 95% confidence intervals are shown on the graphs.
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3, 5, and 7 enabled statistically significant differentiation between mild and mod-
erate to severe AP. We compared these curves with the ROC curve computed for 
CRP determined on day 3 of AP. The AUC values for OPG (0.719–0.825; Figure 1) 
were lower than AUC for CRP [i.e. 0.838 (0.651–1)], although the differences were 
not statistically significant (p >0.05 for all comparisons). OPG concentrations mea-
sured at admission enabled the diagnosis of SAP with sensitivity of 78% and spec-
ificity of 67% at the cut-off value of 587 pg/mL. On day 3, OPG measurements 
achieved sensitivity of 71% and specificity of 80% at cut-off value of 713 pg/mL.
DISCUSSION
In the present study, we investigated serum concentrations of TRAIL and its de-
coy receptor OPG during the early phase (first week) of AP. Starting from day 
3 of the study, we found significant differences in OPG concentrations between 
patients with MAP and SAP, enabling the differentiation between the forms of AP 
with the diagnostic accuracy comparable with that achieved by CRP measure-
ments. Also, OPG concentrations were higher in patients who died from AP and 
were significantly associated with measures related to disease severity, such as 
Glasgow score, CRP concentration and the length of hospital stay. In contrast, 
serum concentrations of TRAIL were not associated with AP severity. OPG/TRAIL 
ratios were weakly associated with the severity of AP and did not enable efficient 
differentiation between MAP an SAP patients in the early phase of AP.
To our best knowledge, this is the first study regarding serum concentrations 
of TRAIL and OPG in AP. Recently, TRAIL mRNA expression has been studied 
in experimental AP in rats [14], but the study was inconclusive as to the role of 
TRAIL in acinar cells apoptosis. TRAIL-mediated apoptosis has been associated 
with chronic pancreatitis [15]. However, serum concentrations of TRAIL cannot 
be directly correlated to local cell expression of TRAIL. Also, cellular actions of 
TRAIL depend on the local expression pattern of various TRAIL receptors [8]. Ev-
idence exist, for example, that TRAIL may exert proliferatory and protective effect 
on pancreatic beta cells [16]. On the other hand, decreased soluble TRAIL has 
recently been associated with incidence and severity of sepsis [17]. To the con-
trary, our AP patients (including those who died) had higher TRAIL concentra-
tions comparing to healthy individuals. The discrepancy may be associated with 
different pathology of the disease states, and partially explained by the fact that 
the majority of our patients had mild disease. 
OPG has been first described as a decoy receptor for receptor activator of 
nuclear factor kappa B ligand (RANKL), involved in a critical signaling pathway 
regulating bone remodeling [18]. Later, OPG has been shown to bind TRAIL, 
blocking its proapoptotic functions. OPG expression has been shown to be in-
duced by various up-stream inflammatory mediators, such as interleukin 1 and 
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TNF-a [19, 20]. Elevated serum OPG has been documented in various conditions 
associated with inflammatory state, i.e. atherosclerosis, where it seems to be 
mainly expressed by vascular endothelial and smooth muscle cells [18, 19, 21], 
chronic kidney disease [22], diabetes [23], or rheumatoid arthritis [24]. Recent-
ly, increased OPG has been associated with the extend of ischemic brain inju-
ry in experimental model in mice [25]. Also, OPG is expressed in pancreas and 
has been linked with type 1 diabetes [20] and pancreatic cancer [26]. In type 1 
diabetes, OPG may act as an auto- or paracrine survival factor, protecting beta 
cells from apoptosis [20], although another group demonstrated that it promotes 
loss of beta cells [27].
The positive correlations between CRP and OPG, that were significant through-
out the study period suggests that in AP patients, OPG may be up-regulated due 
to inflammatory state. From practical point of view, diagnostic sensitivity and 
specificity of OPG for prediction of SAP is comparable to that achieved by day 
3 CRP measurements in our patients, and is also comparable to recent reports 
regarding the diagnostic utility of CRP in AP [28, 29]. However, our results are 
limited by the low number of patients studied and should be confirmed by the 
larger prospective trial.
CONCLUSIONS
Determination of serum OPG concentrations may help in early prediction of se-
verity of AP. However, the diagnostic utility of the measurements, comparable 
to that of CRP, does not enable to use it as a single clinically reliable predictor. 
Still, it seems worth to be further studied in a larger group of patients. In con-
trast, our results suggest that serum TRAIL is not useful in the differentiation 
between mild and severe form of AP.
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